Answers are grounded in this paper and cite their sources.
We have fabricated a clinically relevant size of hCMP with trilineage cardiac cells derived from human induced-pluripotent stem cells. The hCMP matures in vitro during 7 days of dynamic culture. Transplantation of this type of hCMP results in significantly reduced infarct size and improvements in cardiac function that are associated with reduction in left ventricular wall stress. The hCMP treatment is not associated with significant changes in arrhythmogenicity.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: